Abstracts tagged "Patient reported outcomes"

Abstract Number: 1497 • ACR Convergence 2022
How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
Karolina Benesova¹, Oliver Hansen², Uta Kiltz³, Jan Brandt-Juergens⁴, Peter Kästner⁵, Elke Riechers⁶, Daniel Peterlik⁷, Christina Budden⁷, Annika Boas⁷, Stefanie Welle⁷ and Hans-Peter Tony⁸, ¹University Hospital Heidelberg, Heidelberg, Germany, ²Medizinische Abteilung V - Rheumatologie, Universitätsklinikum, Heidelberg, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁶Medizinische Hochschule Hannover, Hannover, Germany, ⁷Novartis Pharma GmbH, Nürnberg, Germany, ⁸Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: In both, ankylosing spondylitis (AS) and psoriatic arthritis (PsA), women typically have a longer delay in diagnosis.1,2 There is scientific evidence that prognosis for…
Abstract Number: 2074 • ACR Convergence 2022
Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study
Tala El Tal¹, Santiago Arciniegas², Sarah Mossad³, Ibrahim Mohamed⁴, Victoria Lishak⁵, Stephanie Fevrier⁶, Lawrence Ng³, Paris Moaf³, Joanna Law³, ashley Danguecan³, Linda Hiraki⁷, Deborah Levy⁸ and Andrea Knight¹, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, ON, Canada 3Institute of Biomedical Engineering, University of Toronto, Brampton, ON, Canada, ⁵The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁶The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), particularly executive dysfunction (ED), with adverse effects on treatment adherence,…
Abstract Number: 0203 • ACR Convergence 2022
Feasibility and Acceptability of Integrating Patient Reported Outcomes Within Routine Care of Rheumatoid Arthritis
Manisha Verma¹, Pragya Singh², MICHAEL KEITH², LYNN GERBER², ROBERT CHAO², ERICA MCBRIDE², Yingxue Zhang², Manirath Srishord² and ZOBAIR YOUNOSSI², ¹Inova Health System, Wynnewood, PA, ²Inova Health System, Falls Church, VA
Background/Purpose: Advancements in measurement science have demonstrated that patient reported outcomes (PROs) can act as supplements to clinical markers for a comprehensive assessment of disease…
Abstract Number: 0393 • ACR Convergence 2022
Are We Meeting Patients’ Treatment Goals with Guideline-Based Therapy for Psoriatic Arthritis?
Christeen Samuel¹, Laura Prichett¹, Thomas Grader-Beck¹, Uzma Haque¹, John Miller¹, Suzanne Grieb² and Ana-Maria Orbai³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine and School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Treatment success from the patients' perspective has not been defined in psoriatic arthritis (PsA). The objective was to determine prevalence and associations of patient-reported…
Abstract Number: 0729 • ACR Convergence 2022
Understanding the Practice and Process of Patient Reported Outcome Measures Collection in North American Pediatric Rheumatology Clinics: A Survey of the Pediatric Rheumatology-Care and Outcomes Improvement Network
Y. Ingrid Goh¹, Esi Morgan², Meghan Ryan³, Beth Gottlieb⁴ and Nancy Pan⁵, ¹Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ²Seattle Children's Hospital, Seattle, WA, ³University of Minnesota, Vadnais Heights, MN, ⁴Cohen Children's Medical Center, Lake Success, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Patients/proxies (Pts) complete patient reported outcome measures (PROMs) to inform their healthcare team about their health status. PROMs completed by Pts prior to their…
Abstract Number: 1019 • ACR Convergence 2022
Association Between Stringent Clinical Measures of Disease Activity and Clinically Meaningful Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: Results from KEEPsAKE 1 and 2 Clinical Trials
Alexis Ogdie¹, Joseph Merola², Roberto Ranza³, Ahmed Soliman⁴, Manish Mittal⁴, Byron Padilla⁵, Sandra Ciecinski⁶, Priscila Nakasato⁷ and Laure Gossec⁸, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Waukegan, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie Inc, Toronto, ON, Canada, ⁸Sorbonne Université, Paris, France
Background/Purpose: Assessment of disease activity in PsA patients is important to evaluate therapeutic response in clinical trials. Patient-reported outcomes (PROs) are evaluated to assess benefits…
Abstract Number: 1351 • ACR Convergence 2022
Development, Implementation, and Usability Testing of a New Rheumatoid Arthritis Patient-Reported Outcomes EHR-based Dashboard: A Mixed-Method Study
Cammie Young¹, Anna Montgomery², Catherine Nasrallah³, Lindsay Jacobsohn⁴, Jennifer Barton⁵, Sara Murray⁴, Jinoos Yazdany⁶ and Gabriela Schmajuk⁷, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, ³UCSF, San Francisco, ⁴University of California, San Francisco, San Francisco, CA, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UCSF, San Francisco, CA, ⁷UCSF / SFVA, San Francisco, CA
Background/Purpose: Shared decision making is a key component of a treat-to-target approach for the treatment of rheumatoid arthritis (RA). We created an EHR tool that…
Abstract Number: 1529 • ACR Convergence 2022
Clinical Nailfold Capillaroscopy Using Dinolite Microscope in Patients with Systemic Sclerosis
Krishnasai Abhishek Madathanapalli¹, Alyssa Williams², Baran Ilayda Gunes², Francis Perry Wilson³, John Pauling⁴, Robyn Domsic⁵, Lan Yu⁶ and Monique Hinchcliff⁷, ¹University of Connecticut School of Medicine, Hartford, CT, ²Yale University, New Haven, CT, ³Yale school of medicine, New Haven, CT, ⁴North Bristol NHS Trust, Bristol, United Kingdom, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, ⁷Yale School of Medicine, Westport, CT
Background/Purpose: The clinical importance of nailfold capillaroscopy (NFC) has grown since its inclusion in the 2013 ACR/EULAR Classification Criteria for systemic sclerosis (SSc), yet few…
Abstract Number: 2087 • ACR Convergence 2022
Prospective Study of Clinical, Laboratory, and Patient-Reported Outcomes of Patients with Systemic Lupus Erythematosus Undergoing Total Hip and Total Knee Arthroplasty
David Fernandez, Insa Mannstadt, Mark Figgie, Peter Sculco, Jason Blevins, Caroline Siegel, Deanna Jannat-Khah, DrPH, MSPH, Carey Ford, Mikhail Olferiev, Dina Greenman, Kyriakos Kirou and Susan Goodman, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with SLE have doubled their utilization of THA and TKA, yet postoperative complications remain high. However, disease specific measures have not been assessed.…
Abstract Number: 0207 • ACR Convergence 2022
Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App
Valentin Hamy¹, Christopher Llop², Christopher W Yee², Luis Garcia-Gancedo³, Aoife Maxwell⁴, Wen-Hung Chen⁵, Ryan Tomlinson³, Priyanka Bobbili², Julien Bendelac², Jessica Landry², Maral DerSarkissian⁶, Mihran Yenikomshian², Elinor A Mody⁷, Mei Sheng Duh² and Rachel Williams³, ¹GlaxoSmithKline, London, United Kingdom, ²Analysis Group Inc, Boston, MA, ³GlaxoSmithKline, Philadephia, ⁴GlaxoSmithKline, Stevenage, United Kingdom, ⁵GlaxoSmithKline, Value Evidence and Outcomes, Philadephia, ⁶Analysis Group Inc, Los Angeles, CA, ⁷Reliant Medical Group, Worcester, MA
Background/Purpose: RA symptoms are typically only assessed intermittently in clinical practice and clinical trials. Digital technologies (wearables, smartphones) can facilitate continuous remote monitoring of patients'…
Abstract Number: 0395 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Juergens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Christina Budden⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: There is a higher prevalence of obesity in patients (pts) with psoriatic disease1. The German non-interventional study AQUILA provides real-world data on the influence…
Abstract Number: 0731 • ACR Convergence 2022
Remote Monitoring of Chronic Inflammatory Musculoskeletal Diseases– Results of the Digireuma Feasibility Study
Diego Benavent¹, Luis Fernández-Luque², María Sanz-Jardón¹, Victoria Navarro-Compán³, Pau Altur², Enrique Calvo⁴, Leticia Lojo⁴, Alejandro Balsa⁵ and Chamaida Plasencia-Rodriguez⁶, ¹La Paz University Hospital, Madrid, Spain, ²AdheraHealth Inc, Palo Alto, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Hospital Universitario Infanta Leonor, Madrid, Spain, ⁵Hospital La Paz Institute for Health Research, Madrid, Spain, ⁶Rheumatology Department, La Paz University Hospital, Madrid, Spain
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMDs) require a tailored follow-up that is limited by the capacity of healthcare professionals. The implementation of innovative…
Abstract Number: 1026 • ACR Convergence 2022
Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis
Paras Karmacharya¹, Courtney Stull², Alisa Stephens-Shields³, M. Elaine Husni⁴, Jose Scher⁵, Ethan Craig⁶, Robert Fitzsimmons³, Soumya Reddy⁷, Marina Magrey⁸, Alexis Ogdie⁹ and Jessica Walsh¹⁰, ¹Vanderbilt University, Nashville, TN, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, ⁴Cleveland Clinic, Cleveland, OH, ⁵New York University School of Medicine, New York, NY, ⁶University of Pennsylvania, Wallingford, PA, ⁷NYU School of Medicine, New York, NY, ⁸Case Western Reserve University, University Hospitals, Richfield, OH, ⁹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁰University of Utah, Salt Lake City, UT
Background/Purpose: Despite significant heterogeneity in psoriatic arthritis (PsA), randomized controlled trials (RCTs) generally enroll a homogenous subgroup of PsA patients (polyarticular similar to rheumatoid arthritis).…
Abstract Number: 1354 • ACR Convergence 2022
Early Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis Using Patient-Reported Outcomes Collected via Mobile Application
Leslie Harrold¹, Patrick Zueger², William Benjamin Nowell³, Taylor Blachley¹, Paul Lakin¹, David Curtis⁴, Laura Stradford³, Shilpa Venkatachalam⁵, Namita Tundia² and Pankaj Patel², ¹CorEvitas, LLC, Waltham, MA, ²AbbVie, Inc., North Chicago, IL, ³Global Healthy Living Foundation, Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, New York, NY
Background/Purpose: Little is known about the impact of upadacitinib (UPA) in rheumatoid arthritis (RA) during the initial weeks of therapy in real-world clinical practice. Our…
Abstract Number: 1775 • ACR Convergence 2022
More Than Half of Patients with Osteoarthritis Have Positive Screening for Fibromyalgia And/or Depression, Feasibly Assessed in Routine Care on Indices Within a Single MDHAQ (multidimensional Health Assessment Questionnaire)
Theodore Pincus¹, Kathryn Gibson², Juan Schmukler¹, Tengfei Li³ and Joel Block¹, ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Sydney, Australia, ³Georgetown University, Washington, DC
Background/Purpose: Osteoarthritis (OA) patients may have widely divergent scores for pain severity vs X-ray joint damage, indicating that elevated OA pain 0-10 visual numeric scale…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].